New Drug Trials

Just found this on the Canadian PBC website, possible conclusions to new drug at end of April 2014: DOUBLE-BLIND PHASE OF INTERCEPT’S PHARMACEUTICALS


Also, the international POISE project for PBC :

Intercept Announces Positive Pivotal Phase 3 POISE Trial Results. NEW YORK, March 16, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced that its international Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) demonstrated that OCA, at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary endpoint of achieving a reduction in serum alkaline phosphatase (ALP) to < 1.67x ULN with a ≥ 15% reduction from baseline and a normal bilirubin level after 12 months of therapy. The proportion of patients meeting the POISE primary endpoint was: 10% in the placebo group, 47% in the 10 mg OCA group and 46% in the 5-10 mg OCA group (both dose groups p < 0.0001 vs placebo) in an intention to treat .................. etc etc

(Seems there is now another drug which will be available in the near future)


You may also like...